-
DepoMed (DEPO) Sell-Off an 'Over-Reaction', Roth Capital Says; PT to $28.50
-
Roth Capital Upgrades DepoMed Inc (DEPO) to Buy
-
Notable Analyst Rating Changes 02/13: (ANR) (ATHN) (NSPH) Upgraded; (DEPO) (REGN) (AEM) Downgraded
-
Roth Capital Downgrades DepoMed Inc (DEPO) to Neutral
-
Morning Movers 10/14: (SHZ) (LOCM) (NAV) (AVL) Higher; (DEPO) (NCMI) (AVII) (INSM) Lower
-
Roth Capital Upgrades DepoMed Inc (DEPO) to Buy
-
Roth Capital Downgrades DepoMed Inc (DEPO) to Neutral
-
Roth Capital Initiates Coverage on Depomed (DEPO) with a Buy

